Home > Browse Issues > Vol.36 No.7
Analysis Results of ATP-Tumor Chemosensitivity Assay In Vitro of 88 Cases of Epithelial Ovarian Cancer
Cui Ying*, Zhou Dan, Li Ye, Shen Guihua, Zhang Siyou
Department of Obstetrics and Gynecology, Beijing Hospital, Beijing 100730, China
Abstract: In this research， we demonstrated the feasibility of ovarian cancer patients in clinical individualized chemotherapy using ATP-tumor chemosensitivity assay (ATP-TCA) in vitro. We examined the heterogeneity of chemosensitivity in ovarian cancer specimens (n=88) using an ex vivo ATP-TCA. The short-term effectiveness of chemotherapy was compared between ATP group and control group. We found that the most active single agent tested was paclitaxel， to which 51.9% of samples were sensitive. The order of the sensitivity is paclitaxel > carboplatin > cisplatin > gemcitabine > topotecan > docetaxel > etoposide > cyclophosphamide > bleomycin. Combinations of agents showed more strong sensitivity cases. The short-term effectiveness rates in ATP group (85.23%) and control group (68.75%) were significantly different. Chemosensitivity testing may provide a practical method of testing new regimens before clinical trials in ovarian cancer patients.
CN
EN